TransMedics Group is trading at $77.01 (-4.63%) in after-hours trading after a mixed second-quarter earnings report saw an earnings miss and rising costs overshadow a revenue beat.
- The company posted $189.9 million in revenue, beating estimates, but diluted EPS of $0.41 missed the $0.50 consensus as operating expenses surged 49%.
- While management raised the low end of its full-year 2026 revenue guidance, the significant cost pressure and earnings miss appear to be the primary drivers behind the share price decline.